+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market Size, Share & Industry Trends Analysis Report By Test Type (Aneuploidy, Chromosomal Abnormalities, X-linked diseases), By Country and Growth Forecast, 2022-2028

  • PDF Icon

    Report

  • 64 Pages
  • April 2022
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5600725
The Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market is expected to witness market growth of 10.7% CAGR during the forecast period (2022-2028).

Preimplantation genetic testing is increasingly being utilized by healthcare practitioners and institutions to identify problems present in embryos before implantation, as it has been shown to be an effective approach for diagnosing genetic disorders. Thus, in the next years, the demand for preimplantation genetic testing will be fueled by the need for better diagnostic methods to combat the increased prevalence of genetic diseases in babies.

Because of the rising number of cases with genetically imbalanced structures observed in children and neonates, preimplantation genetic diagnosis is considered a critical process. Preimplantation genetic diagnosis entails examining an embryo for a specific genetic condition before it implants. PGD is used to ensure that embryos that are not affected by the condition can return to the uterus. The PGD allows researchers to examine the DNA of eggs or embryos in order to select those with specific mutations for hereditary illnesses. When there are early chromosomal or genetic problems in the family, as well as in the context of in vitro fertilization programs, preimplantation genetic diagnostics are useful.

Before a reproductive clinic in Western Australia can generate embryos for PGD, it must first get authorisation from the WA Reproductive Technology Council (Council). This is to ensure that embryo testing is only done when there is a significant chance of a serious genetic problem (rather than for other reasons such as sex selection of embryos, which is illegal in Australia) and that patients have received proper genetic counseling. The Council examines the danger and severity of the condition, the test's safety and reliability, and the condition's impact on both the prospective child and the family before reaching a decision about PGD.

Developing countries such as China and India are participating in a number of reproductive health improvements, which have been supported by the introduction of a number of supportive government legislations.

The China Market dominated the Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $12,387 Thousands by 2028. The Japan Market is poised to grow at a CAGR of 10.1% during (2022-2028). Additionally, The India Market is expected to display a CAGR of 11.4% during (2022-2028).

Based on Test Type, the Market is segmented into Aneuploidy, Chromosomal Abnormalities, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Illumina, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, PacGenomics, CeGaT GmbH, and Laboratory Corporation of America Holdings.

Scope of the Study


Market Segments Covered in the Report:


By Test Type
  • Aneuploidy
  • Chromosomal Abnormalities
  • X-linked diseases
  • Single Gene Disorders
  • HLA Typing
  • Gender selection
  • Others

By Country
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players


List of Companies Profiled in the Report:

  • Illumina, Inc.
  • Invitae Corporation
  • Natera, Inc.
  • Agilent Technologies, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Reproductive Genetic Innovations
  • PacGenomics
  • CeGaT GmbH
  • Laboratory Corporation of America Holdings

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market, by Test Type
1.4.2 Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Test Type
3.1 Asia Pacific Aneuploidy Market by Country
3.2 Asia Pacific Chromosomal Abnormalities Market by Country
3.3 Asia Pacific X-linked diseases Market by Country
3.4 Asia Pacific Single Gene Disorders Market by Country
3.5 Asia Pacific HLA Typing Market by Country
3.6 Asia Pacific Gender selection Market by Country
3.7 Asia Pacific Other Test Type Market by Country
Chapter 4. Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Country
4.1 China Preimplantation Genetics Diagnosis (PGD) Market
4.1.1 China Preimplantation Genetics Diagnosis (PGD) Market by Test Type
4.2 Japan Preimplantation Genetics Diagnosis (PGD) Market
4.2.1 Japan Preimplantation Genetics Diagnosis (PGD) Market by Test Type
4.3 India Preimplantation Genetics Diagnosis (PGD) Market
4.3.1 India Preimplantation Genetics Diagnosis (PGD) Market by Test Type
4.4 South Korea Preimplantation Genetics Diagnosis (PGD) Market
4.4.1 South Korea Preimplantation Genetics Diagnosis (PGD) Market by Test Type
4.5 Singapore Preimplantation Genetics Diagnosis (PGD) Market
4.5.1 Singapore Preimplantation Genetics Diagnosis (PGD) Market by Test Type
4.6 Malaysia Preimplantation Genetics Diagnosis (PGD) Market
4.6.1 Malaysia Preimplantation Genetics Diagnosis (PGD) Market by Test Type
4.7 Rest of Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market
4.7.1 Rest of Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Test Type
Chapter 5. Company Profiles
5.1 Illumina, Inc.
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Regional Analysis
5.1.4 Research & Development Expense
5.2 Invitae Corporation
5.2.1 Company Overview
5.2.2 Financial Analysis
5.2.3 Regional Analysis
5.2.4 Research & Development Expenses
5.3 Natera Inc.
5.3.1 Company Overview
5.3.2 Financial Analysis
5.3.3 Regional Analysis
5.3.4 Research & Development Expenses
5.4 Agilent Technologies, Inc.
5.4.1 Company Overview
5.4.2 Financial Analysis
5.4.3 Segmental and Regional Analysis
5.4.4 Research & Development Expense
5.4.5 Recent Strategies and Developments:
5.4.5.1 Approvals and Trials:
5.5 PerkinElmer, Inc.
5.5.1 Company Overview
5.5.2 Financial Analysis
5.5.3 Segmental and Regional Analysis
5.5.4 Research & Development Expense
5.5.5 Recent Strategies and Developments:
5.5.5.1 Product Launches and Product Expansions:
5.6 Quest Diagnostics Incorporated
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental Analysis
5.7 Reproductive Genetic Innovations
5.7.1 Company Overview
5.8 PacGenomics
5.8.1 Company Overview
5.9 CeGaT GmbH
5.9.1 Company Overview
5.10. Laboratory Corporation of America Holdings
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Segmental and Regional Analysis

Companies Mentioned

  • Illumina, Inc.
  • Invitae Corporation
  • Natera, Inc.
  • Agilent Technologies, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Reproductive Genetic Innovations
  • PacGenomics
  • CeGaT GmbH
  • Laboratory Corporation of America Holdings

Methodology

Loading
LOADING...